Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CeTeG phase III trial of lomustine + temozolomide versus standard temozolomide in newly diagnosed MGMT-methylated glioblastoma
2009-011252-22Phase 3Completed
- Sponsor
- University of Bonn
- Start
- May 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing CCNU/temozolomide + radiotherapy with Standard temozolomide + radiotherapy (2 arms). Primary endpoint: Overall survival. Started May 2010; status: completed.
02
Drugs
lomustinetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-011252-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011252-22.